This Viewpoint discusses whether commonly occuring, sometimes divergent interpretations of new evidence’s validity and usefulness should be explained when experts and guideline committees provide recommendations for screening or treatment.
José López‐Sendón, Karl Swedberg, John J.V. McMurray, Juan Tamargo, Aldo Maggioni, Henry Dargie, Michał Tendera, Finn Waagstein, J Kjekshus, Philippe Lechat, Christian Torp‐Pedersen
Bernhard Paulweber, Paul Valensi, Jaana Lindström, Nebojša Lalić, Colin Greaves, Martin McKee, Katarzyna Kissimova‐Skarbek, Stavros Liatis, E. Cosson, Julia Szendroedi, K. Sheppard, Kate Charlesworth, A. Felton, Michael Hall, Annu-Riikka Susanna Rissanen, Jaakko Tuomilehto, Peter E. H. Schwarz, Michael Roden, M. Paulweber, Andreas Stadlmayr, Lyudmyla Kedenko, Nikolaos Katsilambros, Konstantinos Makrilakis, Zdravko Kamenov,
Mitchell Robinson, Clare Primiero, Pascale Guitera, Angela Hong, Richard A Scolyer, Jonathan R. Stretch, Geoffrey Strutton, John F. Thompson, H. Peter Soyer
Discussion(0)
No comments yet. Be the first to comment.